A study on blood component measurements after consumption of the test food

A study on blood component measurements after consumption of the test food-3-: a randomized, double-blind, crossover comparison study - A study on blood component measurements after consumption of the test food-3-

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000061141

Enrollment

Registered

2026-04-02

Start date

2026-04-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese

Interventions

&lt

Duration&gt

Single ingestion &lt

Test food&gt

Test 1: Test food 1 Test 2: Test food 2 *The intervention sequence is Test 1 followed by Test 2. *The washout period is at least one week. &lt

Test 1: Test food 2 Test 2: Test food 1 *The intervention sequence is test 1 followed by test 2. *The washout period is at least one week.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Japanese 2. Men or women 3. Adults 4. Healthy individuals 5. Individuals whose BMI is >=18.5 kg/m2 and <25 kg/m2

Exclusion criteria

Exclusion criteria: 1. Individuals who are receiving treatment for or have a history of malignant tumors, heart failure, or myocardial infarction 2. Individuals who have an implanted pacemaker or implantable cardioverter defibrillator 3. Individuals who are currently receiving treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, chronic kidney disease, cerebrovascular disease, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic disease 4. Individuals who consume Foods for Specified Health Uses or Foods with Functional Claims 5. Individuals who are taking or using medications (including herbal medicines) or supplements 6. Individuals who are allergic to medications or foods related to the test food 7. Individuals who are pregnant, lactating, or planning pregnancy during this study 8. Individuals who have participated in other clinical studies within 28 days before informed consent, or plan to participate in another study during this study 9. Individuals who have pre-existing gastrointestinal diseases (irritable bowel syndrome, inflammatory bowel disease, gastric ulcer, or gastroesophageal reflux disease) 10. Individuals who are deemed unsuitable for participation in this study by the principal investigator

Design outcomes

Primary

Measure	Time frame
1. The changes in the concentration of astaxanthin compounds in blood 2. Pharmacokinetic parameters	—

Secondary

Measure	Time frame
1. Individuals who experienced adverse events 2. Systolic blood pressure and diastolic blood pressure in Test 1 and Test 2	—

Countries

Japan

Contacts

Public ContactNaoko Suzuki

ORTHOMEDICO Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026